For what it's worth,
In spite of my enthusiasm for this stock over the past three years, my timeline for actual put-up-or-shut-up accomplishments always has been five years.
Right now I'm more confident in what has been accomplished in the way of patentable platform and gene responsible disease and drug response markers than I am in our new CEO's ability to launch us into the drug making business. I, too, am not very impressed with his or Hector Gomez's prior attempts.
However, I believe drug manufacturing would be a natural for DNAP, should fortune smile on all of us and give Gabriel and Gomez credit for past learning experiences enough to translate it into a well thought out and profitable business plan.
From the very beginning, I have been concerned about dirty tricks being played by large pharmas and other parties apparently disinterested in Personalized Medicine but really waiting to pounce when the time was ripe, for example the way GE just did. Who knows what they have been doing in the background to thwart the efforts of small startups getting a foothold in a market they came to realize they want to dominate.
Old money owns GE. They don't want to miss the train the way they did with computer software.
Market Data 
Markets 
AI
